

# D8.8 - RP1 Technical/scientific review meeting documents

Partner: University of Padova (UNIPD)
Lead Author: Sabrina Brigadoi (UNIPD)

Version: F: final;
D: draft; RD: F

revised draft

Date: 12/03/2024





Grant Agreement 101099093 Acronym Prometeus

Project full title Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Deliverable D8.8

Deliverable Name RP1 Technical/scientific review meeting documents

Nature of deliverable R
Dissemination level SEN

Scheduled delivery date 29/02/2024 Actual delivery date 12/03/2024

Prepared by Sabrina Brigadoi

Verified by Marta Pozza

History of Changes										
Revision	Date (dd/mm/yyyy)	Author	Changes	Status (Draft/Inreview/ Submitted)						
v1	11/03/2024	Sabrina Brigadoi	Prepared deliverable	D						



### Table of contents

Histo	ry of Changes	1
	roduction	
2. Fin	nal agenda	3
	t of Attendees	
4. Pre	esentations	6
4.1	Technical Overview of the project	6
4.2	WP1 - Brain oxygenation and perfusion (neo-opticap)	
4.3	WP2 - Continuous Metabolic Monitoring (wearable sensor)	
4.4	WP3 - Metabolic Model and neonatal in silico avatar	
4.5	WP5 - Cloud-based platform (digital cloud twin)	39
4.6	WP7 - The social culture of preterm birth	
4.7	WP8 – Dissemination and Communication	
4.8	Innovation potential and Exploitation presentation	69
4.9	WP8 – Data Management Plan	78
4.10	WP8 – Management	



#### 1. Introduction

This report contains the final agenda, the list of attendees and the presentations of the first review meeting of the Prometeus project.

#### 2. Final agenda





#### PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093

#### 1st Review Meeting agenda

Date and time: 13/03/2024, 9.00 am CET

Meeting location: virtual, via WebEx

Start	End	Event	Speaker
9.00	9.10	Organizational welcome by PO and introduction of all attendees	Alina Maria TOMOIAGA, EISMEA PO
9.10	9.30	Technical overview of the project	Sabrina BRIGADOI, UNIPD
9.30	9.55	WP1 - Brain oxygenation and perfusion (neo-opticap) Progress made in RP1 Main results obtained Deliverables and milestones achieved Problems occurred and solutions DEVIATIONS from the DoA Next steps planned	Davide CONTINI, Polimi
9.55	10.10	Questions and answers	Reviewers, EISMEA and presenters
10.10	10.35	WP 2 - Continuous Metabolic Monitoring (wearable sensor)  Progress made in RP1  Main results obtained  Deliverables and milestones achieved  Problems occurred and solutions  DEVIATIONS from the DoA  Next steps planned	idan TAMIR, QULAB
10.35	10.50	Questions and answers	Reviewers, EISMEA and presenters
10.50	11.05	Break	
11.05	11.30	WP 3 - Metabolic Model and neonatal in silico avatar Progress made in RP1 Main results obtained Deliverables and milestones achieved Problems occurred and solutions	Chiara DALLA MAN, UNIPD

1



		DEVIATIONS from the DoA	
		Next steps planned	
11.30	11.45	Questions and answers	Reviewers, EISMEA and presenters
11.45	12.10	WP 5 - Cloud-based platform (digital cloud twin) Progress made in RP1 Main results obtained Deliverables and milestones achieved Problems occurred and solutions DEVIATIONS from the DoA Next steps planned	Alberto SCARPA, DAVE
12.10	12.25	Questions and answers	Reviewers, EISMEA and presenters
12.25	12.50	WP 7 - The social culture of preterm birth Progress made in RP1 Main results obtained Deliverables and milestones achieved Problems occurred and solutions DEVIATIONS from the DoA Next steps planned	Paola RIGO, UNIPD
12.50	13.05	Questions and answers	Reviewers, EISMEA and presenters
13.05	13.50	Lunch Break	
13.50	14.05	WP 8 - Dissemination and Communication	Sabrina BRIGADOI, UNIPD
14.05	14.35	Innovation potential and Exploitation presentation  General overview of project potential Introduction on PEC Exploitation of subcomponents of the project	Michele LACERENZA, PIONIRS, Prometeus Exploitation Committee member
14.35	14.50	WP 8 - Data Management Plan	Sabrina BRIGADOI, UNIPD
14.50	15.05	WP 8 - Management Deviations from Annex 1 and 2 Use of resources	Sabrina BRIGADOI, UNIPD
15.05	15.20	Break	
15.20	15.35	Exploitation Services offered by EIC &EC	Alina Maria TOMOIAGA, EISMEA PO
15.35	16.15	Assessment meeting by monitors and PO	Reviewers, IR Expert and PO
16.15	16.30	Wrap up by PO	Alina Maria TOMOIAGA, EISMEA PO



#### 3. List of Attendees

UNIPD

▼ Donata

Amato



F	PRC reterm nd met	DMETEUS brain-oxygenation abolic eu-sensing			European Innovation Council  Funded by the European Union
	Pre	eterm Brain-C		Metabolic EU-Sensing: Feed	I the Brain - Prometeus
			Proi	meteus - GA n° 101099093	
			4		
			1st R	eview meeting Participants list	
Partner	÷	Participant Na =	Participant Family r =	email =	role in the project =
DAVE	~	Alberto	Scarpa	alberto.scarpa@dave.eu	WP5 leader
DAVE	~	Manuele	Papais	manuele.papais@dave.eu	WP 5 partner
DAVE	~	Stefano	Dal Poz	stefano.dalpoz@dave.eu	WP 5 Partner PI
ICFO	~	Turgut	Durduran	turgut.durduran@icfo.eu	WP 1 member, Partner PI
ICFO	~	Georgina	Tresànchez Lacorte	georgina.tresanchez@icfo.eu	WP1 member, PhD student
ICFO	~	Mirko	Fornasier	mirko.fornasier@icfo.eu	WP1 member, PhD student
1010		Will KO	T OTTIGGICT	ITIII KU.IUTTIASIEI (WICIO.EU	WP 1 PEC Referee / Partner
PIONIRS	~	Michele	Lacerenza	lacerenza@pionirs.com	Representative
Polimi	~	Alessandro	Torricelli	alessandro.torricelli@polimi.it	WP 1 Partner PI
Polimi	~	Davide	Contini	davide.contini@polimi.it	WP1 leader
Polimi	~	Caterina	Amendola	caterina.amendola@polimi.it	WP1 member
Polimi	~	Fabio	Negretti	fabio.negretti@polimi.it	WP1 member, PhD student
QULAB	~	Idan	Tamir	idan@qulabmedical.com	WP 2 leader, partner PI
QULAB	~	Sharon	Lefler	sharon.l@gulabmedical.com	WP 2 member, partner VP R&D
				Siturorii. (Squadiffication: Com	WP 2 member, partner Head,
QULAB	~	Berta	Ben-Shachar	berta@gulabmedical.com	Bioengineering
UCC	~	Gene	Dempsey	gene.dempsey@gmail.com	WP6 leader and partner PI
UCC	~	Frederic	Adam	fadam@ucc.ie	WP 6 member
UCC	~	Lou	Le Gall	llegall@enssat.fr	WP6-7 software developer
UCC	~	lyshwarya	Stapleton	istapleton@ucc.ie	WP6-7 research fellow
UCL	~	Robert	Cooper	robert.cooper@ucl.ac.uk	WP 1 member, Partner PI
UCL	~	Hubin	Zhao	hubin.zhao@ucl.ac.uk	WP1 member
UdG	~	Josep	Vehí	josep.vehi@udg.edu	WP 4 leader, partner PI
UdG	~	Omer	Mujahid	omer.mujahid@udg.edu	WP 4 member, partner technic, Prometeus Exploitation Committee member
UdG	*	Sara	Casadesús	sara.casadesus@udg.edu	WP 4 member, partner coordinator administrative
LICA	_	E	Daylaiay	Emmanuel.Barbier@univ-grenoble-alpes.	W/D 2 manufact Postman DI
UGA		Emmanuel	Barbier	<u>fr</u>	WP 3 member, Partner Pl
UGA	~	Florence	Fauvelle	florence.fauvelle@univ-grenoble-alpes.fr clothilde.courivaud@univ-grenoble-alpes.	WP3 member
UGA	~	Clothilde	Courivaud	fr	WP3 member, Phd Student
UGA	~	Romane	Salingue	romane.salingue@univ-grenoble-alpes.fr	WP3 member
UNIPD	~	Sabrina	Brigadoi	sabrina.brigadoi@unipd.it	Coordinator PI
UNIPD	~	Chiara	Dalla Man	chiara.dallaman@unipd.it	WP 3 leader
UNIPD	~	Paola	Rigo	paola.rigo@unipd.it	WP 7 leader
UNIPD	~	Hadija	Marchiori	hadija.marchiori@studenti.unipd.it	WP3 member, PhD student
UNIPD	~	Marta	Pozza	marta.pozza@unipd.it	Coordinator administrative staff
		<u> </u>		:	<u> </u>

donatamaria.amato@unipd.it

WP7 member, PhD student



#### 4. Presentations

#### 4.1 Technical Overview of the project

## PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093

#### Technical Overview of the project

- Scientific overview of the project
- Objective and WP organization
- Timeline of the project



This project has received funding from the European Union's Horizon Europe research and innovation programmunder grant agreement No 101099093







#### Prometeus - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain



Survival rate of preterm



Impairment in motor/sensory/cognitive functions







Prematurity associated disability cost for first 2 years of life in Europe

> 50,000 € /year/baby









This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



#### Scientific overview



Transient lack of oxygen and key metabolites



Impact brain development and increase risk for disability

There are currently no tools able to continuously monitor in real-time at the cot-side multi-regional brain health and metabolic fuels




Current guidance for neonatal parenteral nutrition is not targeting brain health or considering multi-metabolites

Parents and HCPs feedbacks are not considered in biomedical devices development







Prometeus groundbreaking technology will shift the paradigm of preterm neonatal care and nutrition, through a **Nutritional Clinical Advisor (NCA)**, that will guide parenteral (intravenous) nutritional intakes of preterm neonates to achieve optimal brain oxygenation

The development of Prometeus technology will be advised by a feed-forward interaction with families of preterms and HCP to shape the new device aiming at incorporating the needs of the final users. This approach will create a novel paradigm for the industrial development of neonatal devices along with an archive for the future scientists and historians of infancy

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



#### Scientific overview



To target brain health through parenteral nutrition

State of art


Operational glucose thresholds to adjust nutritional intakes

#### **Prometeus**

Real-time advice for glucose, lipid and protein intakes to provide individual brain EU-oxygenation and metabolic fit







Real-time monitoring of CBF, StO<sub>2</sub> and CMRO2 from multiple regions at the cot-side

#### State of art

Current devices are either not available for cot-side monitoring (e.g., ASL-MRI) or work at the cot-side but are either too bulky, not ideal for neonatal use or not available for multi-site measurements

#### **Prometeus**

First multi-channel compact miniaturized cot-side device with preterm-optimized head interface for continuous monitoring of brain hemodynamics

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



#### Scientific overview



Real-time minimally invasive monitoring of multi-metabolites at cot-side

#### State of art

Current devices are measuring only glucose and are not adapted for prolonged used in neonates

#### Prometeus

First multi-metabolites (glucose, lactate, BHB) minimally invasive microprobe-based sensor approach







Model of neonatal plasma-brain metabolic response to guide nutrition

#### State of art

Lack of models of the effect of glucose and nutrients on preterm brain hemodynamics

#### Prometeus

Implementation of the first neonatal *in silico* avatar and nutritional clinical advisor (NCA)

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### Scientific overview



#### The digital twin

#### State of art

Parental separation, limited access to information and contacts with HCP and onbody devices in NICU can worsen parents' coping with prematurity

#### Prometeus


Human factor will be considered in Prometeus device development. First European Visual and Oral Archive of prematurity





## **Objectives**






This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP organization






This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093


European Innovation Council



### **Timeline**







This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



4.2 WP1 - Brain oxygenation and perfusion (neo-opticap)

PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093

# WP1: Brain oxygenation and perfusion (neo-opticap)

Davide Contini Politecnico di Milano (PoliMi)







### Outline



- WP Description
- Time-Domain Near InfraRed Spectroscopy (TD-NIRS)
- Speckle Contrast Optical Spectroscopy (SCOS)
- Neo-Opticap Layout
- Optical Probe
- TD-NIRS Module
- SCOS Module
- Conclusions

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### Partners Involvement



Number	Role	Short name	Legal name	Country
1	COO	UNIPD	UNIVERSITA DEGLI STUDI DI PADOVA	IT
2	BEN	QLAB	QULAB MEDICAL LTD.	IL
3	BEN	UdG	UNIVERSITAT DE GIRONA	ES
4	BEN	POLIMI	POLITECNICO DI MILANO	IT
5	BEN	pioNIRS	PIONIRS SRL	IT
6	BEN	ICFO	FUNDACIO INSTITUT DE CIENCIES FOTONIQUES	ES
7	BEN	DAVE	DAVE SRL	IT
8	BEN	UGA	UNIVERSITE GRENOBLE ALPES	FR
8.1	AE	INSERM	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	FR
9	BEN	UCC	UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK	IE
10	AP	UCL	UNIVERSITY COLLEGE LONDON	UK

Neonatology

System integration and WP leading Module TD NIRS Module SCOS

Cloud-based platform (digital cloud twin)


Neonatology Module HEAD CAP

Partner defining needs/constraints from other WPs
Partner designing, building, and testing the neo-opticap






## Tasks and Timing



#### Tasks:

- Task 1.1 (M1-M3) Definition of technical specifications (UNIPD, POLIMI, pioNIRS, UCL, ICFO, Dave, UCC).
- Task 1.2 (M4-M12) Module development (UNIPD, POLIMI, pioNIRS, UCL, ICFO).
- Task 1.3 (M13-M24) System integration (UNIPD, POLIMI, pioNIRS, UCL, ICFO, Dave).
- Task 1.4 (M19-M30) Testing, optimization, and validation (POLIMI, pioNIRS, UCL, ICFO).
- Task 1.5 (M31-M36) Investigational Medical device approval documents (UNIPD, POLIMI, pioNIRS, UCL, ICFO, UCC).
- Task 1.6 (M37-M48) Support to in vivo study and system revision (UNIPD, POLIMI, pioNIRS, UCL, ICFO, UCC).



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



#### Deliverables and Milestones



#### $\label{eq:Deliverable} \textbf{D1.1} - \textbf{Neo-opticap evaluation of performance}$

Deliverable Number	D1.1	Lead Beneficiary	4. POLIMI
Deliverable Name	Neo-opticap evaluation of pe	rformance	
Туре	DEM — Demonstrator, pilot, prototype	Dissemination Level	SEN - Sensitive
Due Date (month)	30	Work Package No	WP1

#### Deliverable D1.2 – WP1 Medical Device Approval Documentation

ation for medical device approval by national authorities

Deliverable Number	D1.2	Lead Beneficiary	4. POLIMI
Deliverable Name	WP1 Medical Device Approv	val Documentation	
Туре	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	36	Work Package No	WP1

Description

Evaluation of performance of the neo-opticap device, report of testing results

#### Deliverable D1.3 – WP1 Revision

D1.3	Lead Beneficiary	4. POLIMI
WP1 Revision		
R — Document, report	Dissemination Level	SEN - Sensitive
48	Work Package No	WP1
	R — Document, report	R — Document, report


Milestone No	Milestone Name	Work Package No	Lead Beneficiary	Means of Verification	Due Date (month)
3	Neo-opticap	WP1	4-POLIMI	Fully operating prototype characterized using standardized protocols based on calibrated phantom Linked tasks: 1.1, 1.2, 1.3, 1.4 Linked deliverables: 1.1	





### Links with other WPs





WP8 - Management, dissemination, exploitation and communication


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## Near-InfraRed Spectroscopy (NIRS)













## **TD-NIRS** Time Domain NIRS





Diffusion approximation of Radiative Transport Equation

 $\mu_a(\lambda), \, \mu'_s(\lambda) \implies$ pathlength

 $\mu_a(\lambda) = \sum \varepsilon_i(\lambda) \, C_i$ 

HHb, O<sub>2</sub>Hb

 $tHb = HHb + O_2Hb$ 

 $S_tO_2 = O_2Hb/tHb$ 




Funded by the European Union


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093


**SCOS** Speckle Contrast Optical Spectroscop

A. Torricelli et al., "Time domain functional NIRS imaging for human brain mapping," NeuroImage (2014) [doi:10.1016/j.neuroimage.2013.05.106]









Intensity autocorrelation function E 0.5 BFI ↑

By measuring speckle contrast (k) at different positions or at different measurement time blood flow index can be recovered simplifying the instrumentation and increasing the SNR.

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

T(S)



## Probe - General Concept









Step One: oam structure placed on



Step Two:
Probes placed into foam construction
and secured with sticker



Step Three: Secure the full array in place by stretching over a breathable stretchy gauze

- Patient comfort.
- Smallest footprint allowing the hosting of the 6 optodes.
- Capability to ensure a good optical contact between optodes and patient head.
- Biocompatibility of all materials that contact the patient.
- Possibility to easily sanitize the probe or make parts disposable.
- No interference between the probe and baby's standard care.


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

European Innovation



## Optode





This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

European Innovation Council






## Optodes - Probe Assembling










This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## Measurement Layout












## Neo-Opticap Layout





### **TD-NIRS Module**







- average output optical power > 2 mW < 5 mW) Automatic equalization of the laser power delivered to the tissue

Two pulsed laser sources at 685 and 830 nm wavelengths (repetition frequency > 50 MHz,


- A single-photon detection module, based on a solid state photodetector, with a photosensitive area larger than 1.5 mm<sup>2</sup>, dark count noise lower than 50.000 counts per second and a temporal resolution better than 150 ps.
  - A TCSPC- based (Time-Correlated Single-Photon Counting) timing electronic, able to measure arrival time of each detected photon with 10 ps resolution and conversion rate higher than 2 million events per second.
- Ad-hoc firmware
- A synchronization and GPIO sub-module.






#### SCOS-Module







This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

- A 785 nm laser with a coherence length >5 m.
- Automatic safety control mechanisms to ensure Laser 1C operation (IEC 60825-1).
- Six ICFO custom SCOS detector modules (~105 independent speckles/detector) and electronics with appropriate optical coupling (~2 pixels/speckle, <0.001 % cross-pixel contamination, ~150 electrons/pixel/frame detection)</li>
- A Dynamic-Linked Library tailored for the control of the module.
- Serial and network interfaces for the real-time transfer of processed data and the periodic transfer of raw data through cloud storage for the latter
- Digital input/output lines for synchronization with the other modules.



#### Conclusions



- Neo-Otpical specs, functionalities and layout defined
- TD-NIRS module under deployment to PoliMi labs from PIONIRS
- SCOS module under deployment to PoliMi labs from ICFO
- First version of the Optical Probe under evaluation by clinical partners
- . Main ancillary modules for integration under test

	Tasks		Y	1			Y2				Y3				Y4			
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	
WPI	1.1																	
	1.2																	
	1.3																	
	1.4				T.	U												
	1.5																Г	
	1.6																П	





## Future (six-months) Steps



- Development of the control Unit
- · Integrating all the modules together
- Writing SW and FW for the synchronization and control of Neo-Opticap
- Optode finalization => Probe finalization

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



4.3 WP2 - Continuous Metabolic Monitoring (wearable sensor)

## PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093



FirstQ<sup>™</sup> - The World's First Minimally-Invasive Patch for Continuous Metabolic Monitoring (CMM)









## WP 2 - Continuous Metabolic Monitoring (wearable sensor)




- 1. Progress made in RP1
- 2. Main results obtained
- 3. Deliverables and milestones achieved
- 4. Problems occurred and solutions
- 5. DEVIATIONS from the DoA
- 6. Next steps planned

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



#### WP 2 - Continuous Metabolic Monitoring (wearable sensor)



#### 1. Progress made in RP1

The work carried by QuLab Medical in the first year of the PROMETEUS project was focused on constructing and mechanically testing a novel patch concept for introducing a minimally invasive, microprobe-based sensor array chip into human skin, positioning these sensors at fixed locations within the dermal layer.

QuLab's novel patch concept included two components: 1. A spring-loaded applicator, 2. A skin-attachable patch with a preloaded microprobe sensor array.


The studies performed in the first year of the PROMETEUS project were divided into four parts:

- 1. In-vitro testing of the patch and applicator using artificial skin.
- 2. Developing and implementing a clean-room assembly protocol for the patch and introducer.
- 3. Developing and validating a sterilization protocol for the patch and introducer.
- 4. Testing the safety and efficacy of the patch and introducer in pigs, including a long-term study of patch implantation safety.






### WP 2 - Continuous Metabolic Monitoring (wearable sensor)



Results: In-vitro testing of the patch and applicator using artificial skin



#### WP 2 - Continuous Metabolic Monitoring (wearable sensor)



Results: Developing and validating a sterilization protocol for the patch and introducer






- Assembly, sterilization and packing lot release for in-vivo validation in pig and FIM studies
- · Six-month shelf life was established for this batch to allow for completion of the first in men (FIM) safety study.






### WP 2 - Continuous Metabolic Monitoring (wearable sensor)




Results: safety and efficacy study of the patch and introducer in pig skin









c: Patch #4, slide #2, needle canal with

d: Representative microprobes (x20 magnification) before (a) and after pig skin insertion and removal (b)

Mechanical and safety validation of the FirstQ applicator and patch were established in-vivo in a pig model.

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093





### WP 2 - Continuous Metabolic Monitoring (wearable sensor)



Results: Long-term (14 days) study of safety patch implantation







- Histological analysis of skin biopsies taken after patch removal following 14-days'
- Overall safety of the FirstQ patch sensor has been confirmed, establishing compliance for clinical studies.





## WP 2 - Continuous Metabolic Monitoring (wearable sensor)



#### 3. Deliverables and Milestones achieved

QuLab Medical (QLAB) leads WP2 of the program. Specific project deliverables for the first year of the PROMETEUS program:

- 1. Obtaining Ethics Committee approval for conducting patch studies in pigs (D2.1 M3).
- 2. Finalizing pig biocompatibility studies (D2.2 M12).


QLAB has successfully accomplished both deliverables, demonstrating the biocompatibility of its patch and microprobe chip components.

QLAB has demonstrated good patch safety and microprobe skin penetration efficacy in pigs, resulting in no microprobe fracture and excellent skin insertion up to a depth of 1mm in live pig skin.

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP 2 - Continuous Metabolic Monitoring (wearable sensor)



- 4. Problems occurred and solutions N/A
- 5. DEVIATIONS from the DoA N/A
- 6. Next steps planned:

For the second year of the project, our objectives are reaching POC for simultaneous and parallel glucose and lactate sensing in pigs and then in humans. We will focus on improving the dynamic range of these sensors to optimally respond to the full physiological concentration of both metabolites, by depositing different limiting membranes on top of the hydrogel that immobilizes the metabolite-specific enzyme.

In the first half of the second year of the program, QLAB is planning to complete its First-In-Man study to demonstrate patch safety and MP skin penetration.





4.4 WP3 - Metabolic Model and neonatal in silico avatar

## PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093

## **WP3 -** Metabolic Model and Neonatal In Silico Avatar

#### Prof. Chiara Dalla Man

Department of Information Engineering University of Padova



Prometeus Annual Review Meeting, March 13th 2024

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093







- University of Padova (UNIPD)
- University of Grenoble Alpes (UGA)
- · University of Girona (UdG)









Development of the mathematical model of glucose, lactate and BHB utilization and production and their effect on CBF, StO2 and CMRO2 (brain hemodynamics).

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## Model Development and Use




- The model will be first developed using the <u>preclinical (animal)</u> data that will be acquired by partner UGA and then <u>revised after</u> our first in human experiment.
- The developed model will be at the basis of the controller developed in WP4 by partner UdG.





### **Tasks**



- Task 3.1 In vivo animal study (UGA, UNIPD)
- Task 3.2 Tracer and MRI analysis (UGA, UNIPD)
- Task 3.3 neonatal in silico avatar (UNIPD, UdG)
- Task 3.4 Metabolic model adaption to human data (UNIPD, UdG)

		Y1					Y2			Y3				Y4			
	TASKS	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
	3.1																
33	3.2																
W	3.3																
	3.4																

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## Progress made in RP1



- · Recruited human resources.
- Approval of the protocol by the Ethical Committee.
- Optimization of the experimental setting for the in vivo animal trial.
- · Theoretical analysis of metabolic paths of the tracers.
- Investigating the possibility to incorporate lactate kinetics in an existing metabolic simulator based on in-house data (proof of concept).

European Innovation Council



### Recruited Human Resources



#### @UGA

- 1 PhD student recruited, began 9/2023 for 3 years Clothilde COURIVAUD
  - → Already trained for animal experiment and animal surgery
- 1 biological engineer recruited, began 11/2023 for 2.5 years Romane SALINGUE.
  - → 2 weeks training for animal experiment (11/2023)
  - → 1 week training for animal surgery (1/2024)

These two trainings are mandatory to work in autonomy

- @UNIPD
- 1 PhD student recruited, began 10/2023 for 3 years Hadija MARCHIORI
  - → Already trained in basic mathematical modeling

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093




## Protocol Approval



#### **Experimental protocol**

- rat pups ~14 days
- · 10 animals per group.
- 6 groups for MRI study and 6 groups for blood tracers quantification




Application to the ethical committee: approved 10/2023 (D3.1, Ethics rats)






## In vivo Animal Study



Currently, UGA is optimizing the various bricks of the experimental protocol and is now able to:

perform early weaning (remove rat pups at 13 days of age from their mother)



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

European Innovation Council

Funded by the European Union

## In vivo Animal Study



- to place venous catheters (arterial catheters: ongoing)
- · to monitor blood glucose over time
- to modify the glycemia using insulin/glucose injection
- to perform cerebral blood flow maps using MRI (adaptation of the cradle, the anesthesia mask).





Femoral artery catheter (left) and venous catheter (right)

Caudal veins catheters




Microcatheter (Doccol's






## In vivo Animal Study



UNIPD and UGA are also optimizing the sampling schedule of the tracers and metabolites to be able to extract from the data as much information as possible



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## In vivo Animal Study




#### **Next steps**

- Tracer injection and detection by NMR and mass spectroscopy.
- Clamp operation to alter glycemia (hypo and hyperglycemia challenges).






## Tracer Analysis



UNIPD analyzed theoretically the metabolic paths followed by the injected

isotopic tracers




†
This project has received funding from the European Union's Horizon Europe research and innovation program/fme\* under grant agreement No 101099093



## Tracer Analysis










## Tracer Analysis






This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## Tracer Analysis











## Mathematical Modeling



- No data available yet
- Working with The Glucose-Insulin-Cpeptide (Human) Simulator (GIC Simulator) and in-house data in the mean time




This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# Mathematical Modeling

PROMETEUS
preterm brain-oxygenation
and metabolic eu-sensing


**Subjects:** 44 obese adolescents (age= $16\pm3$ , BMI= $33\pm8$ ; M/F=23/21) **Protocol:** 75 g OGTT








## Mathematical Modeling Model Development and Selection







This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## Mathematical Modeling



#### **Model Validation**




Mean±SD glucose, insulin, Cpeptide and lactate in silico (continuous line) vs in vivo concentrations (dashed lines).





## Main Results



- · Partners have recruited human resources needed for the projects.
- UGA got the approval of the protocol by the Ethical Committee.
- UGA is ready to start the experiments on rat pups.
- UNIPD successfully integrated a model of lactate kinetics in an already available glucose-insulin-Cpeptide simulator using in-house data

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# Deliverables




	N	Deliverable name	Short description	WP	Leader	Туре	Diss. level	Deliv. date
V	D3.1	Ethicsrats	Ethics approval for animal study	3	UGA	ETHICS	PU	M4
	D3.2	Animal	Evaluation of animal study	3	UGA	R	PU	M30
	D3.3	D3.3 Model & Avatar Evaluation of metabolic model/ avatar		3	UNIPD	R	PU	M32
	D3.4	WP3 Revision	Revision of metabolic model	3	UNIPD	R	PU	M48





## Milestones



Milestone	Milestone name	WP	Due date	Means of verification
3	Metabolic model	WP3	M28	Smulation ( <i>in</i> sili∞) study
6	In silico neonatal avatar	WP3	M30	Software verified and validated

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# **Problems Occurred & Solutions**



- · No postdoc recruited at UGA, PhD instead
- · Delay in ethic authorization
- · Tissue fixation equipment delayed





# Deviation from the DoA



None

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# **Next Step**



- · Performing the experiments on rat pups
- · Analyzing the samples
- · Modeling the data
- · Developing the neonate simulator based on rat data
- · Validating the neonate simulator on human data







# Thank you for your attention

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



4.5 WP5 - Cloud-based platform (digital cloud twin)

# PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093

# WP5 Cloud-based platform (digital cloud twin)


2023/03/13 Alberto Scarpa - DAVE








# WP5 Objectives



develop the Prometeus Cloud-based environment for NICU on-body monitoring.



## Tasks



Task 5.1 Cloud app prototype (UNIPD, Dave, UCC). HCP's app and parents' app will be integrated into the Prometeus platform through the following components: i) PEU (Prometeus Edge Unit): field device which is in close proximity with the sensing devices and the patients and interoperates with the sensors through their docking stations, manages the Controller execution, interoperates with field equipment and other ICT platforms; ii) PCS (Prometeus Cloud Service): cloud platform.


Task 5.2 Communication protocol and interoperability (Dave). Compatibility of the linked devices (connectivity will be set during WP1, WP2) and porting of the control algorithm will be tested: number of connection failures under different environmental scenarios (e.g., distance, on body interference, room temperature); maximum availability, robustness and uptime, especially in the field, which are critical.

Task 5.3 Support in vivo study (Dave). Remote support to the in vivo study in WP6 will be provided through remote assistance. 24/7 personnel will be available for troubleshooting for the investigators at the two sites of UNIPD and UCC. Dave will serve as data management site.

Task 5.4 Prototype revision (UNIPD, Dave, UCC). To account for feedbacks from NICU personnel with respect to the clinical-user interface of Prometeus in NICU environment.








This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# Deliverables and milestones



#### Released:

**D5.1** Specifications of the cloud app (M 4)

**D5.2** Cloud-app Prototype evaluation (M 12)


### Work in Progress:


D5.3 Communication protocol (M 22)





## **D5.1 Process**





This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

# the European Union


# D5.1 Competitors CMM/CGM



















# D5.1 Neopticap



A NOTICE STRUCTURE AND ADDRESS OF THE PROPERTY OF THE PROPERTY


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



preterm brain-oxygenation and metabolic eu-sensing



# **D5.2 Specifications**



	Main topics	Collected specs
Business Requirements	High-level requirements describe the goal and the value of the project/product.	7
User Requirements	User requirements describe what the system should do and how it should work according to the user's point of view. User requirements are designed to satisfy the business requirements.	25
System Requirements	System requirements are the technical requirements needed to satisfy the user requirements.	55

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# D5.1 Use cases



#### Use case 1

#### Setup

This use case includes the activities needed to configure the system before starting a monitoring session.

#### Use case 2

#### Monitoring

This use case is the core functional usage of the system.

#### Use case 3

#### Interaction with parents

This use case describes how the parents at home use the Prometeus system to monitor the health status of their babies while they are hosted at the NICU.

#### Use case 4

#### **Exam Review**

This use case describes the interaction of an HCP with the PCS online to review data from a previous monitoring session.





# Risk Mitigation



#### Inter-device Communications Failures (Likelihood M, Severity M)

Communications will be performed in a timed and smooth way, with backup procedures in case of failures (e.g., guaranteeing a critical message which needs to be delivered to the care facility staff in case of a critical condition requiring immediate assistance)

Sesors are directly connected with the PEU.

**Alarms** generated by the sensors are directly showed to the HCP. PEU shows alarms/errors both on the HMI with red **pop-ups** and with a **sound alarm**.

PEU monitors the **connection status** with the sensors.

If PEU finds a connection problem an alarm for the HCP is shown on the HMI.

Data sent by the sensors and received by the PEU are stored in **local storage** and **syncronized with the cloud platform (PCS)** for backup.

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# D5.2 System Architecture









# D5.2 Hardware selection









Compliance: ISO 60601


- NXP i.MX8M Arm Cortex A53
- Memory: 8 GB LPDDR4
- Al Engine: 2.3 TOPS
- · Connectivity: 2 Ethernet, WiFi, Bluetooth
- 15-21" display touch

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## D5.2 Software Architecture









# D5.2 Dashboard





This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093






# D5.2 Actions and NCA







# D5.2 Events











This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

# D5.2 Alarms, Exams, Settings











D5.2 Demo




# https://prometeus-01.prometeus.tolomeo.io

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# **DEVIATIONS** from the DoA




# No Deviation





# Next steps planned





This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



4.6 WP7 - The social culture of preterm birth

# PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093



Partners involved: UCC, UNIPD












# OB6: The social culture of the preterm birth






### WP7 aims to:

a) evaluate the **potential impact** of on-body monitoring devices on parents and healthcare personnel (HCP) and their personal experience with prematurity

b) create the first Visual and Oral Archive of prematurity, containing longitudinal memories of the experience related to:


- Prometeus devices development
- premature birth

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093






# **Tasks**



Task	Task Labels (from path-finder project)					
7.1	Development of assessment tool (UCC, UNIPD)					
7.2	Ethical Committee Approval for the interview collection (UNIPD, UCC)					
7.3	Script for video recording (UNIPD, UCC)					
7.4	Assessment and interview study for parents and HCP on device development (UNIPD, UCC)					
7.5	7.5 Visual and oral archive of prematurity (UNIPD)					








# **Tasks**



Task	Task Labels (from path-finder project)					
7.1	Development of assessment tool (UCC, UNIPD)					
7.2	Ethical Committee Approval for the interview collection (UNIPD, UCC)					
7.3	Script for video recording (UNIPD, UCC)					
7.4	Assessment and interview study for parents and HCP on device development (UNIPD, UCC)					
7.5	Visual and oral archive of prematurity (UNIPD)					



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# Task 7.1: Development of assessment tool



Task 7.1 was dedicated to the definition of tools to administer to parents 👬 and HCP 🔗 over a longitudinal period.

	Task	Task Labels (from path-finder project)
	7.1	Development of assessment tool (UCC, UNIPD)
	7.2	Ethical Committee Approval for the interview collection (UNIPD, UCC)
	7.3	Script for video recording (UNIPD, UCC)
A	7.4	Assessment and interview study for parents and HCP on device development (UNIPD, UCC)
	7.5	Visual and oral archive of prematurity (UNIPD)

Next step planned: Task 7.4 (Longitudinal data collection)







# Task 7.1: Development of assessment tool









A medical and emotional assessment of the families **M** through a digital diary developed by UCC that takes into consideration the physical and emotional path of each patient to promote empathy and empowerment.

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# Task 7.1: Development of assessment tool







A review of the literature was conducted in March 2023 to investigate which tools were mostly administered on parents of preterm infants and HCP working in NICU.





A psychological assessment of both the families 🕍 and HCP ಿ through standardized questionnaires that investigate personal wellbeing and coping strategies.



UCC and UNIPD selected the following test battery:

- PERMA-Profiler wellbeing
- STAI anxiety
- **BDI** depressive symptoms
- COPE coping strategies
  PPQ PTSD symptoms related to childbirth
- EPDS perinatal/postnatal depression





# Task 7.1: Development of assessment tool









A psychometric assessment of both the families in and HCP at through

- a) standardized questionnaires b) a qualitative ad hoc interview
- example of questions:

Now some situations that occur in the NICU will be listed. We would like to know how stressful these situations are for you.

- 1. The smell in the room where preterm newborns are hospitalized
- 2. To see the newborn inside the incubator

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093





To investigate stressor perception in the NICU and the nurse-parent relationship:

- PSS-NICU stressors perception (parents)
- PS-ICU stressors perception (HCP)
- NSPT perceived support (parents)



To evaluate the impact and perception of Prometeus on-body monitoring devices, we are developing the questions of a qualitative ad hoc interview



# Task 7.2: Ethical Committee Approval



In order to start data collection (Task 7.4), a draft of the entire protocol has to be sent to the Ethical Committee.

The entire protocol (sample and methods) will be the same for UCC and UNIPD.



COMITATO ETICO DELLA RICERCA PSICOLOGICA (AREA 17)
Dipartimenti/Sezione di Psicologia - Università di Padova
Via Venezia 8, 35131, Padova
FAX. -39-0498276600, Email: comitato-icto. area17@mipd.it:
Sito WEB: https://comitati-etici-unipd.scientificnetwork.org/

Univocal code: 111-a Date of approval: 08/07/23




Pending





# Task 7.3: Script for video recording





Task 7.3 is dedicated to develop the scripts to conduct **longitudinal narrative sessions**, that are semi-structured interviews repeated over a 4-month period. The scripts consist of a protocol to follow in both sites when data collection starts, which defines the environment, the details and the open-ended questions of the interview.

The interviews aim to bring out themes related to parents and HCP experience of prematurity.



Task	Task Labels (from path-finder project)
7.1	Development of assessment tool (UCC, UNIPD)
7.2	Ethical Committee Approval for the interview collection (UNIPD, UCC)
7.3	Script for video recording (UNIPD, UCC)
7.4	Assessment and interview study for parents and HCP on device development (UNIPD, UCC)
7.5	Visual and oral archive of prematurity (UNIPD)

Next step planned: Task 7.5 (Archive Creation)



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

European Innovation Council Funded by the European Union

# Task 7.3: Script for video recording






Longitudinal narrative sessions aim to bring out themes related to parents and HCP experience of prematurity.

The scripts were saved in **two** manuals (one for  $\frac{1}{8}$  one for  $\frac{1}{8}$  with the following list of contents:









# Task 7.3: Script for video recording






The scripts of the narrative sessions will be adjusted **in the light of the themes emerged** and then used to perform short interviews, that in turn will become part of the Visual and Oral Archive of Prematurity.

IN PROGRESS: Archive script and training video implementation (D7.1, 31/07/2024).





This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



**PROMETEUS** 

preterm brain-oxygenation and metabolic eu-sensing

# Pilot study



UNIPD conducted a pilot study (may-oct 2023) to test the **feasibility** and **accuracy** of the narrative session script.



Univocal code: 5408 Date of approval: 24/07/2023 Sample: 11 mothers who had a preterm birth. Mother's age: 33-62 (M=39,2). Gestational age: 28-36 weeks (M=33)

**Measure:** online semi-structured interviews. Length: 30-55 minutes
















# Pilot study: Analysis







from Silge & Robinson (2017)

- Text data: import a CSV with UTF-8 encoding
- Tidy text: transform the text in tokenized words
- Preprocessing: remove stopwords (e.g. that, and)
- Sentiment Lexicon: classify the sentiment polarity
- Summarized text: calculate the frequency for each word
- Document-Term Matrix: convert the tidy text in a document-term matrix
- Model: fit a topic model using LDA
- Tidied Model: tidy the model to make handling data easier
- Visualizations: visualize the output



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

## Pilot study: Preliminary results of the sentiment analysis



Sentiment analysis is used to classify the polarity of a given document (Figure 1), emotion analysis gives scores to different emotions (Figure 2). We performed a sentiment and emotion analysis on our data utilizing the specific function "get\_nrc\_sentiment" from the syuzhet package (dictionary selected: NRC Word-Emotion Association Lexicon).

### Positive vs Negative Emotions 0.5 0.4 0.3 0.2 0.1 0.0 Percentage

Figure 1: Percentage of Negative and Positive Emotions




Figure 2: Percentage of emotions: positive (trust, joy, surprise, anticipation) and negative (fear, sadness, anger, disgust).

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093


Funded by the European Union



# Pilot study: Metrics to find k value



We ran the algorithm by varying k from 3 through 9. We are currently evaluating the optimal k value, using "FindTopicsNumber" from the *Idatuning* package, which calculates four different metrics to estimate the most preferable number of topics for a LDA model.




This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# Pilot study: Preliminary results of the topic modeling analysis






This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

European Innovation Council



### WP7: Deviations from DoA - Problems and solutions




- □ We are still developing the questions of the qualitative ad hoc interview to evaluate the impact and perception of Prometeus on-body monitoring devices (task 7.1)
  - □ A draft version of the interview has been prepared (revisions are needed)
  - □ No delays are expected for the next step planned (7.4 Data collection)
- □ UCC Ethical Committee Approval (Task 7.2)
  - Still pending
  - □ No delays are expected for the next step planned (7.4 Data collection)

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# Our team and its impact on young participants





Paola Rigo Associate Professor WP7 Leader



Donata Maria Amato Research Assistant Starting period: 01/02/23



Eugene Dempsey Full Professor



Frederic Adam **Full Professor** 



Research Assistant Starting period: 08/02/24 Starting period: 26/02/24



Research Assistant









4.7 WP8 - Dissemination and Communication

# PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093

#### WP 8 Dissemination and Communication



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### WP 8 dissemination



The PEDR was released on 31st July 2023 as deliverable (D8.3)

<u>Publications</u> (one partner only)

Martelli, F., Pifferi, A., Farina, A., et al. (2024). Statistics of maximum photon penetration depth in a two-layer diffusive medium. Biomedical Optics Express 15(2), 1163-1180

Amendola, C., Maffeis, G., Farina, et al. (2024) Application limits of the scaling relations for Monte Carlo simulations in diffuse optics. Part 1: theory. Optics Express 32(1), 125-150





## WP 8 dissemination



#### Dissemination activities:

Name	Туре	Target Audience	Description of objectives	Status
Presentations to potential partners and investors	Meetings	Industry, business partners, Investors	Fund raising and strategic alliance	Ongoing
Practical lecture on Diffuse Optics and TD-NIRS. Politecnico di Milano, course in Biophotonics 2023, Physics Engineering.	Education and training events	Research Communities, Other	Practical lesson and hands-on session with TD- NIRS devices, one of the optical technology of Prometeus. Presentation of PIONIRS research activities.	Delivered

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP 8 dissemination



CARLA Capsule Milano. Working in photonics in the area around Milan.	Collaboration with EU-funded projects	Research Communities, Citizens, Industry, business partners, specific end user communities, Innovators	Presentation to students about PIONIRS activities and research. Overview on the Prometeus project.	Delivered
Yearly conference of the International Society on Oxygen Transport to Tissue 2023	Conferences	Research Communities, specific end user communities	Presentation of scientific results and preliminary measurements of clinical studies on children, performed with PIONIRS devices, as preliminary steps to Prometeus technology validations.	Delivered





### WP 8 dissemination



Yearly Meeting of the Biomedical Photonics Network 2023	Conferences	Research Communities, citi zens, specific end user communities, Innovators, Civil Society	Presentation of scientific results and preliminary measurements of clinical studies on children, performed with PIONIRS devices, as preliminary steps to Prometeus technology validations.	Delivered
OPTICA - From PhD to CEO seminar series, within the Planks 2023 (final of the Physics Olympics).	Clustering Activities	Research Communities, citizens, Industry, business partners	Seminar to students about PIONIRS activities, research projects (comprising Prometeus aim and preliminary results) and personal experiences within the company.	Delivered

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### WP 8 dissemination



Invited talk at	Conferences	Research	Presentation of	Delivered
Innovación para		Communities,	scientific results	
a salud 2023		specific end user	and preliminary	
		communities	measurements	
			as preliminary steps towards	
			Prometeus	
			technology	
			development.	
			Invited talk	
			Hospital General de México	
			Durduran T.	
			(ICFO)	





### WP 8 dissemination



Next planned dissemination activities:

1<sup>st</sup> workshop at the end of 2024 2<sup>nd</sup> workshop at the end of 2025 3<sup>rd</sup> workshop mid 2026 4<sup>th</sup> workshop at the end of the project (Jan 2027)


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### WP 8 communication




Website and social media (X (former Twitter), Instagram, LinkedIn)



Prometeus (Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain] is a project aimed at introducing a new-paradigm for personalized nutrition of prematurely born neonates in neonatal intensive care unit (NICU). It will develop a groundbreaking technology for real-time adjustment of glucose and nutrients intakes to target neonatal brain needs. The brain of a baby born prematurely is highly susceptible to early neonatal injuries that, in time, increase the first for neurodevelopmental disability provision of adequates insential and proper brain development and growth. However, current nutritional strategies are unfit to target real-time brain necessities, and are driven by pre-specified (non personalised) nutritional charts, in the absence of contemporary cot-side monitoring of both brain "health" and metabolic supplies. As a consequence, sudden changes of brain fuel-requirements cannot be promptly addressed by real-time adjustment of glucose and nutrients provision.







#### Communication activities:

Partner Short Name	Communication Activity Name	Description	Target audien		Communicati on channel	Outcome	Status	
UNIPD	Informed family program	Yearly seminaries at the reference country institution targeting families	Specific user communities (if applicable)	(confined work into debate table discontinuous)	eeting, rkshop, ternet	Online animated cartoon showing in a simple and dedicated language the project's aims and partners involved. In English with subtitles. A few months of delay.	Postponed	Multiple partners

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP 8 communication



UNIPD	Visual Identity	Design of the project logo and development of a common visual identity, including a standard format for presentations.	Citizens	Other	General promotional products have been released: project logo, standard template for deliverables,QRcode linked to Prometeus website (created at month 2 and shared with partners)	Delivered
DAVE	Media	Announcement of the Prometeus Project on the DAVE website https://www.dave.eu/it/news-and-media/news/dave-embedded-system-tra-i-partner-di-prometeus	Industry, business partners	Website	received by 3930 visitors read by 12 visitors	Ongoing







PIONIRS	Social Media	PIONIRS Post presenting project. Linked-in: https://www.linkedin.com/feed/update/urn:li:activity:7061254394394157056 Twitter: https://twitter.com/pionirsit/status/1655492347390	Citizens	Social media	410 views on linkedin 365 views on Twitter	Delivered
PIONIRS	Social Media	PIONIRS Post with a preview of PROMETEUS-related results to be presented at BMPN 2023 event: https://www.linkedin.com/feed/update/urn:li:activity:7143153616911060992	Research communities	Social media	650 views	Delivered

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP 8 communication



ICFO	Event	High School British School of Barcelona visit to ICFO	Citizens	Event (conferenc e, meeting, workshop, internet debate, round table, group discussion m, etc.)	25 students & teachers	Delivered
PIONIRS	Media	Dedicated page on PIONIRS website (https://www.pionirs.com/wp/prometeus-project/) describing the aim of the project, its consortium composition, with a link to the official project website.	Citizens	Website	150 unique visitors since page creation (September 2023)	Ongoing







PIONIRS	Event	PIONIRS booth at ECBO/Laser world of photonics 2023 event (Munich), showcasing its products an activities. Information about PROMETEUS project presented on booth live screen and to audience.	Research communities	Exibition	Event audience: around 1000 persons. Estimated engagement at boot: 5%	Delivered
UDG	Media	UdG Research group website: Post describing the project, partners and objectives of Prometeus. On the official web of the UdG, Post of the press release.	Citizens	Website	57 visits	Ongoing

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP 8 communication



PIONIRS	Event	PIONIRS booth at ISOTT 2023 conference (Tokyo), showcasing its products an activities. Information about PROMETEUS project presented on booth live screen and to audience.	Research communities	Exibition	Event audience: around 200 persons. Estimated engagement at booth: 50%	Delivered
PIONIRS	Event	PIONIRS booth at fNIRS Italy 2023 conference (Padova), showcasing its products an activities. Information about PROMETEUS project presented on booth live screen and to audience.	Research communities	Exibition	Event audience: around 100 persons. Estimated engagement at booth: 80%	Delivered







UNIPD	Website	Creation of a dedicated website translated into the partner languages.	Citizens	Website	The website has been online since early April and fully operational since April 28th 2023. The content has been translated in the partners' languages.	Ongoing
UNIPD	Social Media	Project dedicated pages on Linkedin and Twitter describing the project objectives and aim and informing about its start	Citizens	Social media	Average of 109 views on Linkedin Average 415 views on Twitter	Ongoing

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093




## WP 8 communication



UDG	Social Media	UdG Post on Linkedin and twitter informing of the start of the project and it's main objectives + Post informing about the in- person plenary meeting that took place in Padova		Social media	604 Impressions on LinkedIn - 500 impression on twitter	Delivered
UDG	Media	UdG Press release for the achievement of the project	Citizens	Press release	The article was sent to 167 journalists in Spain and it was shared on different channels.  Newspapers: Diari de Girona, El Punt Avui. Online: Europa press, El Gerió, La vanguardia, el Punt avui, Diari de Girona, Gente digital.	1







UNIPD	Media	UNIPD Press releases announcing the start of the project issued by the University of Padua and local newspapers	Citizens	Press release	364 visits, of which 104 in the first month to news, connection to UNIPD press release, news picked up by local newspapers, permanent place on the website of the department hosting the project	Delivered
-------	-------	---	----------	------------------	--	-----------

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



# WP 8 Open science



All publications so far are in Open Access and have been deposited to <a href="https://re.public.polimi.it/">https://re.public.polimi.it/</a> (POLIMI is member of EOSC) and are available on the Prometeus website


Future publications will follow the same open science practices, as established in the PEDR. Each partner will deposit their pubs in their institutional or non-commercial repositories

Data recorded so far (WP2 and WP7) are being organized as planned in the Data Management Plan as FAIR (further details in the DMP presentation)





# WP 8 Open science



To ensure reproducibility of development results of WP2, Qulab Medical has implemented a Quality Management System (QMS) according to ISO 13485:2016 guidelines

The entire patch development process has been documented in Design Inputs and Reviews accordingly

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



#### 4.8 Innovation potential and Exploitation presentation

# PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093



EXPLOITATION PLAN (PEC)

PEC: Prometeus Exploitation Commette







### PROMETUS IMPACT



#### EARLY BRAIN MONITORING

Neonatal brain hypoxia 80% incidence in preterm Reduction of European healthcare prematurity costs (5 y period)

25 M€ -> 5M€

#### METABOLIC LONGTERM MONITORING

reduce injury due to the **metabolic unbalance** on the growing brain


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

2



### PROMETUS Market size - HEMO











### PROMETUS Market size - GLUCOSE





#### €189B is the total annual diabetes cost (direct & indirect) in Europe

 Leading companies in glucose sensors (DexCom, Medtronic, Abbott) have not yet proposed any device for neonatal monitoring due to their prevailing interest in adult/pediatric diabetes market.


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093


4



### Multilevel exploitation Stages







#### PROMETEUS FULL PLATFORM EXPLOITATION


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093


5





### Multilevel exploitation Stages





#### PROMETEUS SUB-COMPONENT EXPLOITATION

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

6


European nnovation Council



#### • PROMETEUS competitors:

- Big companies are mainly focussed on ADULTS and Continuous Glucose Monitoring (CGM).
- Novel Start-ups -> CGM and APP for tracking and guidance no MDR. (LEVELSHEALTH - SUPERSAPIENS - VERI)
- PROMETEUS: Harsh clinical environment - first time integration with CEREBRAL MONITORING
- · CGM (at clinical study level)

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093







European Innovation





## **Exploitation admin**



#### IP protection and administration:

Within the consortium:

- · Art 8 (CA): Ownership of results: including joint ownership and transfer of results
- + Art 16 (GA) + annex 5
- Art 9 (CA): Access Rights: Access right for exploitation and for implementation

#### IP plan:

- · Continuous monitoring at WP LEVEL each partner
- Continuous monitoring at GLOBAL level -> Prometeus Exploitation Committee (PEC)

This project has received funding from the European Union's Horizon Europe research and linovation programme under grant agreement No 101099093

8



### PEC: Prometeus Exploitation Committee



#### Aim and objectives

PEC should help in preparing the transition towards industrial and commercial usage of the developed products.

Focusses on: intellectual property management to freedom-to-operate and market analyses, coordination of activities related to regulatory documentation, to product and service profiling in liaison with industry, academia, and end-users. [WHAT TO FILE – WHEN TO FILE – HOW TO FILE]

• PEC composition -> PIONIRS | ICFO | UDP | UdG | QULAB | (DAVE) 6/10 partners are directly represented in the PEC

#### Planning

Regularly, each partner will produce a list of the project's outputs that will be submitted to the PEC for evaluating their future exploitation and/or market potential and the adoption of the right protection measures. PEC will benefit from the advice of the The European IP Booster Metagroup to support the "sustainability" of Prometeus over time.

European Innovation Council Funded by the European Union



PEC constitution

#### PEC First official meeting



Brain oxygenation and perfusion (neo-opticap)

Continuous Metabolic Monitoring (wearable sensor)

Metabolic Model and neonatal in silico avatar


Prometeus Nutritional Clinical Advisor (NCA)

Cloud-based platform (digital cloud twin)

First in human

The social culture of preterm

Management expl / comm



#### PEC achievements:

- · Definition of roles inside the PEC
- First level identification of exploitable outcomes


12 exploitable results

7 products + 5 services

First level exploitation approach



# Exploitation - Optical Neuromonitoring



**Platform** 

**PIONIRS POLIMI ICFO** UCL

**PARTNERS** 

Cerebral TD-NIRS & **SCOS** monitoring **NEOPTICAP** 

**EXPL. RESULTS** 

COMPETITORS

Research grade: Smal-medium companies [Artinis - NIRx -Gowerlabs - Kernel - Oxiprem]

Clinical market: big medical company [Medtronics -Edwards - Masimo] **END USERS** 

Research institutions Market size: 100 M€

Clinics Market size: 0.5B€

> 5 years

< 5 years

ACTUAL STAGE: prototype multichannel device + sub-components + electronics development / patent

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

11





### Exploitation - Glucose monitoring



**PARTNERS** 

EXPL. RESULTS

**COMPETITORS** 

**END USERS** 

QLAB

Continuous Multimetabolite Monitoring Patch

Abbott, Dexcom, Medtronic and other smaller-size companies Diabetic patients: Market size: >€3.0B

< 5 years

General population (wellness) Market size: >€10.0B

> 5 years

ACTUAL STAGE: Microprobe-based multi-metabolite monitoring patch + Introducer + Electronics development / patent

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

12

European Innovation Council

Funded by the European Union

### Exploitation - Digital Twin - NCA



**PARTNERS** 

**EXPL. RESULTS** 

**COMPETITORS** 

END USERS

UdG

Nutritional Clinical Advisor for Personalized Brain Nutrition Recommendation Small-medium companies (Healthy-longer, MindX Sciences, OXYPREM)

Big companies/ Cognitive health market (Novartis, Huma, Johnson&Johnson, Biogen) Neonatal Intensive Care
Unit, Healthcare
providers, pump
manufacturers
Market size: Neonatal
Intensive Care Market

Intensive Care Market

Intensive Care Unit, Healthcare providers, pump manufacturers (Medtronic, Lilly, Roche etc.)

Market Size: Neonatal + adult market

< 5 years

> 5 years

ACTUAL STAGE: NCA controller development


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

13





# Identified exploitable results



Exploitable results	Consortium owner/s	IPR plan/status	Type innovation  IPR plan/status (e.g. services, new product, new process)  Next steps		Potential customers /users	Responsible for dissemination
Interoperable App	Dave	industrial design / copyrights	service	SW development	IntensiveCareUnit: Healthcareproviders	Dave
Continuous metabolic monitoring (CMM)	QLAB	industrial design / patent	product/revice		sensor and pump manufacturers (Meditronic, Doxcom, Abbott, Insulot, Lilly, Roche) pharmaceuticals ([Linkcon, Sanofi)	CEAB
Novel hydrogel formulations for improved sensor performance	QLAB	industrial design / patent	product	HW development	Sensor and pump manufacturers (Meditronic, Dexcom, Abbott)	QLAB
Electronic circuitry architecture supporting multi-channel electrochemical signal collection and processing	CLAB	industrial design / patent	product/service		sensor manufactures	QLAS
Neo-opticap	UCLPOLIMI,ICFO, PIONIRS	industrial design / patent	product	HW development	Neuroimaging manufacturers (NifixMedTech, ArtinisMedicalSystem, Gowerlabs)	uici.
Nutritional clinical advisot (NCA) controller	UdS	utility model	product/service		Intensive Care Unit, Healthcare providers, pump manufacturers (Braun, BD Alans, Medtronic, Ully, Insulet, Roche)	uels
Prematurity Visual & Oral Archive	UNIPO	copyright			Proterms' Families and patients, Historians of Science, Psychologists; Exhibitions; Manufacturers / Industries of preterm accessories / medicaldevices	UNIPD
insilico neonatal avatar	UNIPD	copyright			Neonatologists, Biologists, Bioengineers	UNIPO
Nutritionalrecommendations	UNIPD, UdG	freely available / open source			Neonatologists; Neonatal Cochrane; Policymakers	UNIPD
OEM SCOS module	ICFO	gatented	new product	Validation and deployment	Research Labs and clinicians	ICFO
Multi-channel FW upgrades	PIONIRS	industrial design / copyrights	new product	Validation and deployment	Research institutions, clinics	PIONIRS
Optical Switch for multi channel TD NIRS	PIONIRS - POLMI	industrial design / patent	New product	Prototype validation and deployment	optical system manufacturers	PIONIRS/POUMI

Work in progress...

Preliminary evaluation

12 exploitable results

7 products + 5 services

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



EU innovation network and European Medicine Agency (EMA) Innovation services.



#### Strengthening life-sciences innovation across Europe

Tuesday, 21 November 2023

https://www.ema.europa.eu/en/events/strengthening-life-sciencesinnovation-across-europe-eu-innovation-network-conference

- · European Innovation Network (EU-IN)
- Health Products Regulatory Authority (HPRA)
- European incubators and technology transfer offices (TTOs)

power and support the translation of innovative biopharmaceutical and medical technology developments.

MDR: regulatory support / contacts and clinical trials

Service name	Date of attendance	Attendees	Recommendations/follow up actions
Strengthening life-sciences innovation across Europe: EU-Innovation Network conference	21/11/2023	- Michele Lacerenza(PIONIRS) - Miguel-Angel Moreno (ICFO) - Omer Mujahid (UdG)	None, but as a comment, we would appreciate more time dedicated to EMA and EU offers rather than presentations of start-ups incubators and TTOs





# PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093



Thank you!

PEC: Prometeus Exploitation Commette

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093















4.9 WP8 - Data Management Plan

# PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093

#### WP 8 Data Management Plan



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093








The DMP was released on 31st July 2023 as deliverable (D8.4)







### Type of studies

WP1	WP2	WP3	WP4	WP5	WP6	WP7
Phantom and in-vivo adult studies to test stability and precision of neo-opticap	In-vivo animal studies (pigs) to test CMM sensor biocompatibili ty and accuracy	In-vivo animal studies (rat litters) to create the metabolic model (tracers, MRI, liquid chromatograp hy-mass spectrometry, histology)	In-silico testing of the NCA controller to estimate safety and efficacy	None	In-vivo studies in the preterm population to test the feasibility of using the Prometeus technology	Interviews, standardized questionnarie s and narrative sessions for parents and HCPs to evaluate prematurity experience

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### WP 8 DMP



### Type of data

WP1	WP2	WP3	WP4	WP5	WP6	WP7
Quantitative	Quantitative & qualitative	Quantitative	Quantitative	None	Quantitative	Quantitative & qualitative
Time-series, optical measurements; Projects and drawings of instrument and modules design	Images	Images; Tissue samples; Blood samples	Generated with simulation		Clinical measurements (time-series, nutritional information, blood samples, blood plasma); Personal data	From interviews and questionnaires; video-audio recordings; personal data
Tb	20-100 Gb	Gb	Gb		Gb	Gb







#### Format and software

WP1	WP2	WP3	WP4	WP5	WP6	WP7
Drawings: Industrial standards and confidential Non-standard software developed by each lab (Matlab, R, Excel, custom-software)	Word, Excel			None	Data from the sensors will be received by the edge application via HTTPS REST or Bluetooth; Stored inside the edge device on a local databased synchronized with cloud	Qualtrics, Zoom, Cloud Speech-to- text (Google)
Binary and text files	.docx, .xlsx, .jpg	. nifti	.csv format			.csv, .xlsx, .mp4, .mp3, .doc

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### WP 8 DMP




#### FAIR data: Findable

WP1	WP2	WP3	WP4	WP5	WP6	WP7
Non confidential data part of publications: Recognized data sharing repository (e.g., Zenodo)	Dataset identifiable and locatable through DOI	Rules for directory tree in storing preclinical data	Simulated data: stored in Research Data Unipd (a content of OpenAIRE). DOI assigned to each dataset	None	Data store with following metadata (patient ID, health care provider ID, hospital ID, sensor type, start/end date/time)	Anonymized interviews/nar rative sessions: Research Data Unipd. Raw data: stored in external encrypted hard-disks Phaidra for the Archive







#### FAIR data: Accessible

WP1	WP2	WP3	WP4	WP5	WP6	WP7
Data confidential will be secured	Data with IP protection will be kept closed	Embargo until first publication		None	PEC will identify proper licences	
	Data deposited using DOI format and accessible through common search tool	Data deposited on zenodo.org with DOI	Simulated data available in Research Data Unipd	None	Data stored for entire project duration up to max 3 years after	Interviews and questionnaire: Research Data Unipd Archive: openly licensed in Phaidra

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093  $\,$ 



### WP 8 DMP




#### FAIR data: Interoperable

WP1	WP2	WP3	WP4	WP5	WP6	WP7
Forward compatible formats and/or open-source binary formats and/or custom-made binary formats	Interoperable through common SW tools	Interoperable according to standards in each field	csv file is a standard format that can be easily exported in several software	None	Data will be interoperable according to the standards of each field	Phaidra offers excellent interoperability with other platforms (e.g., Europeana)







#### FAIR data: Reusable

WP1	WP2	WP3	WP4	WP5	WP6	WP7
Data stored in the cloud and on secure hard-drive Best practice defined by IT departments for computer use	All data will be reusable under licence after project finalization	All data reusable according to consortium guidelines	Simulated data stored in repository for project's duration and up to 5 years after	None	Data will be reusable according to consortium guidelines	Data will be reusable according to consortium guidelines

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093  $\,$ 



### WP 8 DMP




#### Allocation of resources

WP1	WP2	WP3	WP4	WP5	WP6	WP7
No additional	Data stored in	Data will be	Research Data	None	Clinical data	Research Data
resources	the cloud	available on	Unipd does		stored in the	Unipd and
needed	during project	zenodo with	not require		cloud. Cost is	Phaidra do not
Expertise	duration	no cost	any expense		part of DAVE's	require
already	After project	involved	WP3 leader		budget	expenses
present	ends, data		will be		WP5 leader	Coordinator
No additional	sent to the		responsible		will be	will be
costs since	coordinator		for data		responsible	responsible
already	for further		management		for data	for data
budgeted	storage				management	management

# All partners will identify a Data Manager who is responsible of data storage and preservation







#### Data security

WP1	WP2	WP3	WP4	WP5	WP6	WP7
Sensible data stored in a secure way Transmission of data using private area of project website or certified platforms	No personal data collected Access to other non-disclosable information through cloud using usernames and passwords	Preclinical data stored in centralized services of UGA (duplicated in different locations, access via login and password)	No problem of security for simulated data	None	Access to the system with login and password Encryption for data from sensors to the cloud Database encrypted and protected by passwords Daily/weekly backup	Only PI and authorized personnel will have access to personal data Encrypted NAS or server with institutional restricted access for data storage Data backup

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093  $\,$ 







#### Ethical aspects

Personal data collection compliant with GDPR EU 2016/679


UNIPD and UCC: organizational measure to safeguard privacy of subjects' involved (DPOs appointed -> privacy@unipd.it, gdpr@ucc.ie)

Participants will be allowed to accept/refuse publication of the interview or publish only anonymized scripts

Confidentiality: all subject data will have a unique identification number (no identifiable patient's name when stored)







No changes to the DMP have been applied so far

Only WP2 and WP7 have currently collected data

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093  $\,$ 



### WP 8 DMP - WP2



WP2 dataset on pig not yet completed. Once completed -> DOI


So far, data have been saved using record names and version numbering (ISO 13485 QMS guidelines)

Data are stored in a cloud drive

IP-sensitive information protected by restricted access to such data

European Innovation Council





#### 4.10 WP8 – Management

# PROMETEUS - Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain

Grant Agreement Number 101099093

### WP 8 management


- Deviations from Annex 1 and Annex 2
- Use of resources







### WP 8 management - Deviations from Annex 1



#### Deliverable D9.4 Ethics Advisor

- Rejection of first appointment proposal requested experience in both neonatal clinical trials and ethics aspects
- Proposal to appoint Dr. Westerman-den Boer endorsed at the beginning of March 2024
- Delay counterbalanced by the implementation of clinical trials in year 4

#### Deliverable D3.1 - Ethics rats

- few months of delay in getting the ethics approval for the animal study of WP3
- start preliminary development experiments on mice, using existing approved protocols
- · No expected delays in final results

#### Seminar "Informed families" 1st year postponed

- · online animated cartoon showing the project's aims and partners
- · few month delay for administrative issues

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### WP 8 management - Use of resources



#### Person-months - distribution on linear basis (Annex 1 GANTT activities)

#### STAFF EFFORT

Participant	WP1	WP2	WP3	WP4	WP5	WP6	WP7	WP8	WP9	Total Person-Months
1 - UNIPD	8.00	1.00	24.80	6.60	1.00	13.20	33.50	27.00		115.10
2 - QLAB		82.00						2.00		84.00
3 - UdG			4.00	36.00				2.00		42.00
4 - POLIMI	33.00							3.00		36.00
5 - pioNIRS	18.00							8.00		26.00
6 - ICFO	44.00							2.80		46.8
7 - DAVE	1.00	1.00		7.00	43.00	7.00		5.00		64.0
8 - UGA			67.40							67.4
8.1 - INSERM			10.20					1.00		11.2
9 - UCC	1.00	1.00			10.00	34.00	25.00	2.00		73.00
10 - UCL	14.60							0.60		15.20
Total Person-Months	119.60	85.00	106.40	49.60	54.00	54.20	58.50	53.40	0.00	580.70








	Participant		WP1	WP2	WP	3	WP4	WP5		WP6	WP7	WP8	WP9	Total Person-Month
	1 - UNIPD		8.00	1.00		24.80	6.6	io	1,00	13.20	33.50	27.00		115.1
	PM	WP		% Plan for RP1	ned	% for F		Deviat reporti			nned to	used fo	r given	% Used of planned for entire period
	1 UNIPD	WP1		6.97%		2.55	5%	Materr			of UNI	PD par	ticipant	0.64%
		WP2		0.87%		0.34	%	Materr			of UNI	PD par	ticipant	0.08%
		WP3		28.82%		15.5	52%	PhD s	tude	ent hired	at mont	h 9		3.87%
		WP4		0%		0%		WP 4	start	s at mon	th 13			0%
JNIPD		WP5		0.87%		0.34	1%	Materi			of UNI	PD par	ticipant	0.08%
		WP6		0%		0%		WP 6	start	s at moti	n 30			0%
		WP7		38.93%		43.7	'6%		n the	e first yea	rces than ar with re			10.90%
		WP8		23.53%		17.2	27%		ture	cation w	exploi ill have r . Materi	nore rele		4.30%
		TOTAL		100.00%		79.7	78%							19.88%

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093






# WP 8 management - Use of resources PM



Participant		WP1	WP2	WP3	WP4	WP5		WP6	WP7	WP8	WP9	Total Person-Months
2 - QLAB			82.00							2.00		84.00
3 - UdG				4.00	36.00					2.00		42.00
'			WP	% Plann for RP1	ed % for RF			ntion from reporting p	planned to eriod	used for	% Used planned f entire period	
QULAB		2. QULAB	WP2	97.62%	94.71		Slight delay activit	s in the	hat does no progress	ot result in of planned	23.68%	
			WP8	2.38%	2.38%						0.60%	
			TOTAL	100.00%	97.10	%					24.27%	
	•											_
			WP	% Plann for RP1	ed % Use RP1		Devia given	ition from reporting p	planned to eriod	used for	% Used planned to entire period	or
		3. UdG	WP3	88.89%	89.119				time dev	oted than n plan.	9.55%	7
UdG			WP4	0%	22%				ivities. No		2.36%	
			WP8	11.11%	3.33%		comm			we more with respect	0.36%	
			TOTAL	100.00%	114.4	1%					12.26%	
	Į											











Participant	WP1	WP2	WP3	WP4	WP5	WP6	WP7	WP8	WP9	Total Person-Months
4 - POLIMI	33.00							3.00		36.00
5 - pioNIRS	18.00					l.		8.00		26.00
		WP	% Planned for RP1	% Used for RP1		n from plan porting perio	ned to used to	or % Use planne entire period		
Polimi	4 Polimi	WP1	91.67%	63.56%	the first distribut	year compa	ource utilisation ared with a line writies, there a planned.	ar		
		WP8	8.33%	9.11%			used are a l			
		TOTAL	100.00%	72.67%				18.179	6	
		WP	% Planned for RP1	% Used for RP1		n from plan	ned to used to	or % Use planne entire period		
PIONIRS	5 PIONIRS	WP1	69.23%	26.92%	the first distribut deviatio time the	year compa ion of activit ns from plar	ource utilisation ource with a line ies, there are inned. Addition d was spent out of the staff.	ar io al		
		WP8	30.77%	11.54%	lower, n	o deviation ination and s will be n	used are a la from planne de exploitation propered exploitation pr	d. n		
		TOTAL	100.00%	38.46%				9.62%		

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093






# WP 8 management - Use of resources PM



PROMETEUS
preterm brain-oxygenation
and metabolic eu-sensing

	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	% Used of planned for entire period
6 ICFO	WP1	94.02%	66.67%	Despite lower resource utilisation the first year compared with a linear distribution of activities, there are no deviations from planned. Main issue has been related to the hiring of the personnel. Temporary solution found.	16.67%
	WP8	5.98%	3.42%	Though resources used are a bit lower, no deviation from planned.	0.85%
	TOTAL	100.00%	70.09%		17.52%

**ICFO** 










1	Participant	WP1	WP2	WP3	WP4	WP5	WP6	WP7	WP8	WP9	Total Person-Months	
	7 - DAVE	1.00	1.00		7.00	43.00	7.00		5.00		64.00	

DAVE


	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	% Used of planned for entire period
7 DAVE	WP1	2%	1.60%	Despite lower resource utilisation the first year compared with a linear distribution of activities, no deviations from planned.	0.31%
	WP2	2%	1.36%	Despite lower resource utilisation the first year compared with a linear distribution of activities, no deviations from planned.	0.27%
	WP4	0%	1.36%	Small anticipation of WP4 preliminary activities. No deviation from overall plan.	0.27%
	WP5	86%	60.24%	Despite lower resource utilisation the first year compared with a linear distribution of activities, no deviations from planned.	11.77%
	WP6	0%	0%		0%
	WP8	10%	10.64%	Though resources used are a bit higher, no deviation from planned	2.08%
	TOTAL	100.00%	75.20%		14.69%

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093







# WP 8 management - Use of resources PM



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093





European Innovation Council Funded by the European Union





Participant	WP1	WP2	WP3	WP4	WP5	WP6	WP7	WP8	WP9	Total Person-Months
9 - UCC	1.00	1.00		1	10.00	34.00	25.00	2.00		73.00

UCC

	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	% Used of planned for entire period
9 UCC	WP1	0%	0%		0%
	WP2	0%	0%		0%
	WP5	0%	0%		0%
	WP6	0%	0%		0%
	WP7	0%	0%		0%
	WP8	0%	0%		0%
	TOTAL	100.00%	0%	Though participation in the project is continuous and steady, the partner's activities will be spread mostly over the coming years. No deviations from planned. Problem in recruiting a post-doc candidate (recruited a clincal fellow and RA form month 13).	0%

Ga	ntt (re		ing	per		s in	red	, de	ŝive		les	n g	ree	n)			
	Tasks		,	1	1113		Y	2	223		,	3	202		_ `	4	
4		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
-	1.1			_	_	ш			ш				ш	ш			
ч	1.2	ш				_		_	_					ш			
3	1.3	ш				н							_	ш			
۶	1.4	Н				Н					Ш		-	_			
-1	1.5	Н		Н					-				-	_	_	_	
4	1.0	-	_	-	-	$\vdash$	_	_	-	_	-	_	_		_	-	-
-	2.1			н	-	-	-	Н	-				н	Н		Н	Н
1	2.3	10										-	-	Н		Н	⊢
WP2	24		Н	-	•	-	-						н	Н			Н
>	2.5	Н		Н			-							Н		Н	⊢
1	2.6	Н	-	-		Н					•	ΞV				Н	Н
Л	2.7		-	Н		Н						-	•			-	
-	3.1			-			_	_			_	_	_		_	_	-
-	3.7		•	-	100						ı						Н
8	3.2	Н															
1	3.4										•	•					
	4.1			_			=	=	_					$\overline{}$	_	_	_
9	4.2					п					п						
š	4.3										_						п
П	44												٦n				Г
П	5.1 5.2 5.3						_	_			П				П		П
WPS	5.2								L								
≥	5.3																
9	6.1	ш														Ц,	L
3	6.1 6.2 7.1			_		$\perp$											ш
1	7.1				ш.	_								ш			
ы	7.2	Н				_	_		_				_	_			
1	7.3	Н		Н		-	•	ш					-	Н			
Н	7.4		-	-			-		ш		n		-		-	-	Н
+	8.1	-	_	_	-	-	_	_	=		-	-	=	_	_	-	-
88	8.2								-								
۶Į	8.3		8						=		•						
+		-	_	_	_	_	_	_	_		_	_	_		_	_	_
-	2 3	~		Н					-				-	Н			Н
1	- 2			Н	-	Н			•		_		-	Н		H	⊢
2	3			-		Н					¥		ш				
Milestones	4										•						
	3										•						
	6											•					
1	7											•					
1	8																
	9																


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



**PROMETEUS** 

preterm brain-oxygenation and metabolic eu-sensing

## WP 8 management - Use of resources PM



1000 1000


UCL

	for RP1	RP1	reporting period	planned for entire period
WP1	96.05%	35.53%	Hiring of the PDRA has been delayed. Due in July, will now likely be May. However, this will not have a negative impact on the project, since UCL's contribution to the project is relatively small and does not block other work as long as delieverables are met in years 2 and 3. Major difference is due also to a linear distribution of effort.	8.88%
WP8	3.95%	9.74%	A little more time spent on management activities for a linear distribution of effort	2.43%
TOTAL	100.00%	0%		11.32%
	WP8	WP1 96.05%  WP8 3.95%	WP1 96.05% 35.53%  WP8 3.95% 9.74%	WP1 96.05% 35.53% Hiring of the PDRA has been delayed. Due in July, will now likely be May. However, this will not have a negative impact on the project, since USLs and the project of the project, since USLs and does not block other work as long as delieverables are met in years 2 and 3.  Major difference is due also to a linear distribution of effort.  WP8 3.95% 9.74% A little more time spent on management activities for a linear distribution of effort

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093

European Innovation Council





ANNEX 2

#### ESTIMATED BUDGET FOR THE ACTION

				E	stimated eligible <sup>1</sup> cost	ts (per budget categor	<del>3</del> )					Estimated EU	contribution <sup>2</sup>	
				Direc	t costs				Indirect costs		EU co	ntribution to eligible	costs	Maximum
		A. Personnel costs		B. Subcontracting costs		C. Purchase costs		D. Other cost categories	E. Indirect costs <sup>3</sup>	Total costs	Funding rate % <sup>4</sup>	Maximum EU contribution <sup>5</sup>	Requested EU contribution	grant amount <sup>6</sup>
	A.1 Employees (or ea A.2 Natural persons to	,	A.4 SME owners and natural person beneficiaries	B. Subcontracting	C.1 Travel and subsistence	C.2 Equipment	C.3 Other goods, works and services	D.2 Internally invoiced goods and services	E. Indirect costs					
	A.3 Seconded person	s												
Forms of funding	Actual costs	Unit costs (usual accounting practices)	Unit costs <sup>7</sup>	Actual costs	Actual costs	Actual costs	Actual costs	Unit costs (usual accounting practices)	Flat-rate costs <sup>8</sup>					
	a1	a2	a3	ъ	c1	c2	c3	d2	e=0,25 * (a1 + a2 + a3 + c1 + c2 + c3)	f=a+b+c+d+e	U	g = f * U%	h	m
1 - UNIPD	312 500.00	0.00	0.00	0.00	10 000.00	0.00	49 300.00	0.00	92 950.00	464 750.00	100	464 750.00	464 750.00	464 750.00
- QLAB	520 000.00	0.00	0.00	0.00	15 000.00	10 000.00	5 000.00	0.00	137 500.00	687 500.00	100	687 500.00	687 500.00	687 500.00
- UaG	212 600.00	0.00	0.00	0.00	9 000.00	0.00	2 000.00	0.00	55 900.00	279 500.00	100	279 500.00	279 500.00	279 500.00
- POLIMI	161 000.00	0.00	0.00	0.00	10 000.00	20 000.00	25 000.00	0.00	54 000.00	270 000.00	100	270 000.00	270 000.00	270 000.00
- pioNIRS	109 160.00	0.00	0.00	0.00	5 000.00	0.00	30 000.00	0.00	36 040.00	180 200.00	100	180 200.00	180 200.00	180 200.00
- ICFO	202 000.00	0.00	0.00	0.00	14 000.00	15 200.00	47 000.00	0.00		347 750.00	100	347 750.00	347 750.00	347 750.00
- DAVE	281 600.00	0.00	0.00	0.00	7 000.00	0.00	12 000,00	0.00	75 150.00	375 750.00	100	375 750.00	375 750.00	375 750.00
- UGA	224 500.00	0.00	0.00	0.00	8 000,00	\$ 000.00	53 160.00	0.00	73 415.00	367 075.00	100	367 075.00	367 075.00	367 075.00
1.1 - INSERM	101 000.00	0.00	0.00	0.00	5 000.00	0.00	0.00	0.00	26 500.00	132 500.00	100	132 500.00	132 500.00	132 500.00
- UCC	315 305.00	0.00	0.00	0.00	6 000.00	2 000.00	36 000.00	0.00	89 826.25	449 131.25	100	449 131.25	449 131.00	449 131.00
0 - UCL														
Σ совлог€нив	2 439 665.00	0.00	0.00	0.00	89 000.00	55 200.00	259 460.00	0.00	710 831.25	3 554 156.25		3 554 156.25	3 554 156.00	3 554 156.00

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP 8 management - Use of resources ODC



	Direc	t costs		
	B. Subcontracting costs		C. Purchase costs	
	B. Subcontracting	C.1 Travel and subsistence	C.2 Equipment	C.3 Other goods, works and services
Forms of funding	Actual costs	Actual costs	Actual costs	Actual costs
	ь	c1	c2	c3
1 - UNIPD	0.00	10 000.00	0.00	49 300.00




OTHER DIRECT COSTS	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	
1.	WP6	0%	0%		0%
UNIPD	WP7	0%	0%		0%
	WP8	100%	68.59%	Meetings with participants held in remote mode and the first face-to-face meeting (plenary) held at UNIPD, Psychology campus spaces made available free of charge. No significant deviations from plans.	9.25%
	TOTAL	100.00%	68.59%		9.25%












	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	
2. QULAB	WP2	100%	72%	Meetings held mostly online and one plenary meeting attended in Padua. Difference due to a linear distribution of travel costs in budget.	9%
	WP8	0%	0%		0%
	TOTAL	100.00%	72%		9%

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP 8 management - Use of resources ODC









	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	
3. UdG	WP3	0%	0%		0%
	WP4	0%	0%		0%
	WP8	100%	116.72%	First plenary in person meeting hosted at UNIPD. Difference due to linear distribution of travel budgeted costs.	7.96%
	TOTAL	100.00%	116.72%		12.26%











	TOTAL	100.00%	74.22%		7.68%
	WP8	33.33%	19.13%	First plenary in person meeting hosted at UNIPD. Other meetings held online.	1.98%
4 Polimi	WP1	66.67%	55.08%	The small difference between budgeted and actual is due to a linear distribution of budgeted costs for equipment and supplies. No deviations to report.	5.70%
	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093





## WP 8 management - Use of resources ODC








	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	
5 PIONIRS	WP1	90%	85%	No deviations from plans. Costs related to consumables (electronic components, optomechanical) for prototyping, assembling and testing of the TD-NIRS module of NeoOpticap.	31.9%
	WP8	10%	8.25%	- In-person consortium meeting at UNIPD (2 persons), all other meetings held online Travel and lodging for a dissemination event (conference) in Bern, CH (BMPN2023).	2.8%
	TOTAL	100.00%	93.25%		34.7%













	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	
6 ICFO	WP1	71.43%	6.52%	Main issue has been related to the hiring of the personnel during the first months of the project. This also meant a lower expenditure of other goods and services.  During the next month's till the end of the project, the expense will be compensated.	0.45%
	WP8	28.57%	0%	No travel costs in the first period. Most meeting held online. Difference is due to a linear distribution of travel costs for management purposes.	0%
	TOTAL	100.00%	6.52%		0.45%


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093






## WP 8 management - Use of resources ODC

















	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	% Used of planned for entire period
8. UGA	WP3	70.59%	65.78%	No equipment was purchased in the first year as planned. Costs will be included in subsequent RPs.	4.04%
	WP4	0%	0%		0%
	WP8	29.41%	25.69%	Kick-off meeting and other meetings held online.	1.58%
	TOTAL	100.00%	91.47%		5.62%


This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093






## WP 8 management - Use of resources ODC

















	TOTAL	100.00%	83.33%		17.05%
	WP8	16.67%	0%	Most meetings held online.	0%
9 UCC	WP6	83.33%	83.33%		17.05%
	WP	% Planned for RP1	% Used for RP1	Deviation from planned to used for given reporting period	

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



### WP 8 management - Deviations from Annex 2




- Budget
  - no major budget deviations to report
- Change of "A. Personnel costs" for PIONIRS and DAVE
  - change does not result in budget transfers except within macro-item A1 and A2 to A4 SME owners





# WP 8 management - Deviations from Annex 2



PIONIRS	1.Pers	onnel costs		
	A.1 Employees (or equivalent) A.2 Natural persons under direct contract A.3 Seconded persons		A.4 SME owners and natural person beneficiaries	тот
Forms of funding	Actual costs	Unit costs (usual accounting practices)	Unit costs	
	a1	a2	a3	
GA Annex 2 budget	109 160.00	0.00	0.00	109 160.00
New budget with A.4	39 890.24	0.00	69 269.76	109 160.00

PIONIRS		STAFF EFFORT					
	GA Annex 2 budget	2 New budget with A.4					
	Actual costs	Actual costs	Unit costs SME owners				
WP 1	20.00	10.00	10.00				
WP 8	6.00	2.00	4.00				
tot	26.00	12.00	14.00				

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101099093



## WP 8 management - Deviations from Annex 2



DAVE	1.Perso	onnel costs		
	A.1 Employees (or equivalent) A.2 Natural persons under direct contract A.3 Seconded persons		A.4 SME owners and natural person beneficiaries	тот
Forms of funding	Actual costs	Unit costs (usual accounting practices)	Unit costs	
	a1	a2	a3	
GA Annex 2 budget	281 600.00	0.00	0.00	281 600.00
New budget with A.4	261 808.64	0.00	19 791.36	281 600.00

DAVE		STAFF EFFORT				
	GA Annex 2 budget	New budget with A.4				
	Actual costs	Actual costs	Unit costs SME owners			
WP 1	1	0	1			
WP 2	1	0	1			
WP 3	0	0	0			
WP 4	7	0	7			
WP 5	43	2	41			
WP 6	7	1.50	5.50			
WP 7	0	0	0			
WP 8	5	0.50	4.50			
tot	64	4	60			





# WP 8 management - Meetings



